Rep. Lois Frankel bought Charles River Laboratories International (CRL)
Rep. Lois Frankel (D-FL-22) · $1K–$15K · traded Apr 25, 2023
- Transaction
- Bought
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Apr 25, 2023
- Disclosed
- May 19, 2023
- Days to disclose
- 24
- Asset type
- Stock
- As filed
- Charles River Laboratories International, Inc.
- Industry
- Medical - Diagnostics & Research · Healthcare
Other trades in this filing
- May 19, 2023$1K–$15K
$1K–$15K · Traded May 3, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
$1K–$15K · Traded May 3, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
$1K–$15K · Traded May 3, 2023 · disclosed May 19, 2023
Got $4K from the company’s PAC - May 19, 2023$1K–$15K
$1K–$15K · Traded May 1, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
Sold (partial) Boston Scientific BSX
$1K–$15K · Traded May 1, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
Bought The PNC Financial Services Group PNC
$1K–$15K · Traded Apr 26, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
Sold (partial) PPG Industries PPG
$1K–$15K · Traded Apr 26, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
$1K–$15K · Traded Apr 24, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
Sold (partial) The Hershey Company HSY
$1K–$15K · Traded Apr 24, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
$1K–$15K · Traded Apr 24, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
Bought The PNC Financial Services Group PNC
$1K–$15K · Traded Apr 19, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
$1K–$15K · Traded Apr 19, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
Sold (partial) PPG Industries PPG
$1K–$15K · Traded Apr 19, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
$1K–$15K · Traded Apr 19, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
Sold (partial) Boston Scientific BSX
$1K–$15K · Traded Apr 19, 2023 · disclosed May 19, 2023
- May 19, 2023$1K–$15K
Sold (partial) EPAM Systems EPAM
$1K–$15K · Traded Apr 19, 2023 · disclosed May 19, 2023
Recent Congress trades in CRL
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Sold Charles River Laboratories International CRL
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
Bought Charles River Laboratories International CRL
$15K–$50K · Traded May 8, 2025 · disclosed Jun 22, 2025
- May 31, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
Sold Charles River Laboratories International CRL
$1K–$15K · Traded May 15, 2025 · disclosed May 31, 2025
- May 8, 2025$15K–$50K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
Bought Charles River Laboratories International CRL
$15K–$50K · Traded Apr 8, 2025 · disclosed May 8, 2025
- Feb 12, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Dec 5, 2024$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Nov 15, 2024 · disclosed Dec 5, 2024
- Nov 8, 2023$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Charles River Laboratories International CRL
$1K–$15K · Traded Oct 2, 2023 · disclosed Nov 8, 2023
- Oct 10, 2023$1K–$15K
Rep. Lois Frankel (D-FL-22)
Sold Charles River Laboratories International CRL
$1K–$15K · Traded Sep 8, 2023 · disclosed Oct 10, 2023
Company context for CRL
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
CRL: third_quarter 2026 lobbying report
Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.
Public: Oct 20, 2026, 9:28 PM EDTOriginal source ↗CRL: second_quarter 2026 lobbying report
Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues related to preclinical testing safety assessments, including New Approach Methodologies and virtual control groups Issues surrounding improvements to clinical research capabilities and modernization of research methods. Issues surrounding improvements to clinical research capabilities and modernization of research methods.
Public: Jul 20, 2026, 10:36 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.